Non-idiopathic Scoliosis Clinical Trial
Official title:
Blood Loss and Transfusion Requirement in Pediatric Patients With Non-Idiopathic Scoliosis Treated With Tranexamic Acid Undergoing Posterior Spinal Instrumentation and Fusion.
Investigation of tranexamic acid (TXA) for reducing perioperative blood loss and transfusion requirement in pediatric patients with secondary scoliosis undergoing posterior spinal fusion.
To investigate whether tranexamic acid (TXA) reduces perioperative blood loss and transfusion
requirement in pediatric patients with secondary scoliosis undergoing posterior spinal
fusion.In addition determination of the optimal TXA dosing for perioperative reduction of
blood loss and transfusion requirement as well as to evaluate use of thromboelastography
(TEG) as a measure of coagulation and fibrinolysis in pediatric patients with secondary
scoliosis undergoing posterior spinal fusion (this may help guide blood product therapy).
The investigation will determine the effects of TXA on the TEG profile and whether
plasminogen activator inhibitor-1 (PAI-1) level affects bleeding and transfusion requirement
during scoliosis surgery. Finally to investigate whether PAI-1 level affects bleeding in
response to TXA during scoliosis surgery.
;